Author:
McLeod Donald C.,Baker Danial E.,Campbell R. Keith
Abstract
Pentoxifylline is approved by the Food and Drug Administration for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. It is not a substitute for surgical bypass or removal of arterial obstructions, but will improve function and symptoms of the disease state. The mechanism by which pentoxifylline works is not well known, but appears to be related to erythrocyte adenosine triphosphate (ATP) concentrations and the phosphorylation of erythrocyte membrane proteins, both mechanisms resulting in an improvement in erythrocyte flexibility. Efficacy studies indicate that pentoxifylline is significantly more effective than placebo or nylidrin therapy. Adverse reactions are mainly of the gastrointestional type and are minimized by the use of a controlled-release dosage form.
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference36 articles.
1. Vasodilator Drugs in Peripheral Vascular Disease
2. AMA Division of Drugs. AMA drug evaluations, 5th ed. Chicago, IL: American Medical Association, 1983: 674–80.
3. Petersdorf RG, Adams RD, Braunwald E., Isselbacher KJ, Martin JB, Wilson JD, eds. Harrison's principles of internal medicine, 10th ed. New York: McGraw-Hill, 1983: 1491–8.
4. IMPAIRED RED CELL DEFORMABILITY IN PERIPHERAL VASCULAR DISEASE
5. Red Cell Deformability and Capillary Blood Flow
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献